Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Cellares raises $277 million in its Series D round, with ARK Invest contributing $20 million. The funding will support advancements in cell therapy manufacturing.

PRIVATEJun 09, 2026•2 months ago

Amount Raised

$277 Million

Round Type

Series D

South San FranciscoManufacturingBiotechnology

Investors

Willett AdvisorsDfj GrowthDc Global VenturesGates FrontierEdbiIntuitive VenturesDuquesne Family OfficeBaillie GiffordT. Rowe Price Investment Management, Inc.EclipseBlack RockArk Invest

Description

Cellares has secured $277 million in its Series D financing, including a $20 million investment from ARK Invest. The funds will be used to enhance cell therapy manufacturing capabilities and support commercial-scale operations. Cellares is focused on transforming the manufacturing process with automation and innovation. This funding comes as the company signs a 10-year supply agreement with Cabaletta Bio and delivers its first doses to patients.

Company Information

Company

Cellares

Location

345 ALLERTON AVE

South San Francisco, California, United States

About

Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company’s Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. Cell Shuttles will be deployed in Cellares’ Smart Factories around the world to meet total patient demand for cell therapies at global scale. Partnering with Cellares enables academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand.

Related People

Suggested for you

1 contact

Verified contactsFabian G., Co-Founder & CEO hidden hidden

Predictive Intelligence

Strategic

ML-powered predictions for Cellares's next move

Learn about Strategic plan

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech